Characters | Histology/stage | Patients (n) | Median | Percentage/range |
---|---|---|---|---|
Age |  |  | 56 years | 20–78 years |
Histology | Serous | 85 | Â | 56.7% |
Endometrioid | 41 | Â | 27.3% | |
Mucinous | 9 | Â | 6.0% | |
Clear cell | 6 | Â | 4.0% | |
Mixed type | 9 | Â | 6.0% | |
FIGO stage | I–II | 28 |  | 18.7% |
III–IV | 122 |  | 81.3% | |
Histological grade | G1 | 38 | Â | 25.3% |
G2 | 67 | Â | 44.7% | |
G3 | 45 | Â | 30.0% | |
Tumor residual size | 0 cm | 42 |  | 28.0% |
≤ 1 cm | 71 |  | 47.3% | |
> 1 cm | 37 |  | 24.7% | |
Tumor size | ≤ 10 cm | 67 |  | 44.7% |
> 10 cm | 83 |  | 55.3% | |
Platinum-based | Cisplatin-based | 31 | Â | 20.7% |
Carboplatin-based | 119 | Â | 79.3% | |
Follow-up time |  | 150 | 36.5 months | 2–86 months |